Drugs for DMD, Ebola and Marburg could be approved in 2013. Better yet DMD plus a rapid response platform against virus and bacterial threats. Given that Ebola and Marburg are under the two animal rule and they are in human safety testing (that is the last step before NDA), fast track could make both of these drug approved and ready for stockpiling in 2013. With all the unrest in the world now, the military will absolutely want to stockpile the two drugs for potential bioterrorism defense. The full potential of the company is rising to the surface.
Of course, the helpful things about the Marburg and Ebola drugs is that the military is footing the bill for testing by way of their $280M grant to SRPT. Even if Ebola funding is not continued, Marburg funding will pull it through to a platform designation. All lights are green now! Revenue estimates for 2014 may be above $1B.